📣 VC round data is live. Check it out!

Biotalys Valuation Multiples

Discover revenue and EBITDA valuation multiples for Biotalys and similar public comparables like Brazil Potash, Arctic Fish Holding, Agrokasa, Terra Santa and more.

Biotalys Overview

About Biotalys

Biotalys NV is an agricultural technology company focused on addressing food protection challenges with proprietary protein-based biocontrol solutions and aiming to provide alternatives to conventional chemical pesticides for a more sustainable and safer food supply.


Founded

2013

HQ

Belgium

Employees

64

Financials (LTM)

Revenue: $3M
EBITDA: ($16M)

EV

$149M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Biotalys Financials

Biotalys reported last 12-month revenue of $3M and negative EBITDA of ($16M).

In the same LTM period, Biotalys generated ($16M) in EBITDA losses and had net loss of ($17M).

Revenue (LTM)


Biotalys P&L

In the most recent fiscal year, Biotalys reported revenue of $2M and EBITDA of ($16M).

Biotalys is unprofitable as of last fiscal year, with EBITDA margin of (920%) and net margin of (1046%).

See analyst estimates for Biotalys
LTMLast FY202320242025202620272028
Revenue$3M$2M---
EBITDA($16M)($16M)($22M)($13M)($16M)
EBITDA Margin(487%)(920%)---
EBIT Margin(530%)(1052%)---
Net Profit($17M)($18M)($24M)($15M)($18M)
Net Margin(535%)(1046%)---

Financial data powered by Morningstar, Inc.

Biotalys Stock Performance

Biotalys has current market cap of $154M, and enterprise value of $149M.

Market Cap Evolution


Biotalys' stock price is $3.38.

Biotalys share price decreased by 0.1% in the last 30 days, and by 38.5% in the last year.

Biotalys has an EPS (earnings per share) of $-0.40.

See more trading valuation data for Biotalys
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$149M$154M-0.1%-0.1%69.6%-38.5%$-0.40

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Biotalys Valuation Multiples

Biotalys trades at 45.8x EV/Revenue multiple, and (9.4x) EV/EBITDA.

See NTM and 2027E valuation multiples for Biotalys

EV / Revenue (LTM)


Biotalys Financial Valuation Multiples

As of June 2, 2026, Biotalys has market cap of $154M and EV of $149M.

Biotalys has a P/E ratio of (8.8x).

LTMLast FY202320242025202620272028
EV/Revenue45.8x84.8x---
EV/EBITDA(9.4x)(9.2x)(6.9x)(11.4x)(9.2x)
EV/EBIT(8.6x)(8.1x)(6.1x)(9.5x)(8.1x)
P/E(8.8x)(8.4x)(6.4x)(10.0x)(8.4x)
EV/FCF(8.5x)(9.2x)(6.8x)(10.0x)(9.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Biotalys Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Biotalys Margins & Growth Rates

Biotalys grew revenue by 203% but EBITDA decreased by 10% in the last fiscal year.

In the most recent fiscal year, Biotalys reported EBITDA margin of (920%) and net margin of (1046%).

See estimated margins and future growth rates for Biotalys

Biotalys Margins

Last FY2026202720282029
EBITDA Margin(920%)(274%)
EBIT Margin(1052%)(290%)
Net Margin(1046%)(298%)
FCF Margin(920%)(335%)

Biotalys Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth203%---
EBITDA Growth(10%)(40%)24%(10%)
EBIT Growth(16%)(35%)17%(16%)
Net Profit Growth(14%)(36%)19%(14%)
FCF Growth10%(32%)8%10%

Data powered by FactSet, Inc. and Morningstar, Inc.

Biotalys Operational KPIs

Biotalys' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $0.3M for the same period.

Access forward-looking KPIs for Biotalys
LTMLast FY202620272028
Rule of 40(406%)-
Bessemer Rule of X(285%)-
Revenue per Employee-$0.0M
Opex per Employee-$0.3M
G&A Expenses to Revenue-373%
R&D Expenses to Revenue428%887%
Opex to Revenue-1052%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Biotalys Competitors

Biotalys competitors include Brazil Potash, Arctic Fish Holding, Agrokasa, Terra Santa, Nordic Halibut, FirstFarms, T&G Global, Gobarto, Boa Safra and Seeka.

Most Biotalys public comparables operate across Agriculture.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Brazil Potash--(4.1x)(4.8x)
Arctic Fish Holding3.0x2.6x(93.8x)35.5x
Agrokasa----
Terra Santa9.4x-390.5x-
Nordic Halibut10.3x7.6x31.6x279.8x
FirstFarms3.6x-18.7x-
T&G Global0.5x-8.8x-
Gobarto0.3x-8.7x-

This data is available for Pro users. Sign up to see all Biotalys competitors and their valuation data.

Start Free Trial

Biotalys VC Funding History

Before going public, Biotalys raised $68M in total equity funding, across 4 rounds.


Biotalys Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Mar-20Series CNovalis LifeSciences$11M-Biotalys NV, a Ghent-based agtech company, develops protein-based biocontrols as alternatives to synthetic pesticides for food and crop protection. The company's platform uses agrobodies, camelid antibodies that encapsulate active substances, targeting fungicides and insecticides in the $51.2 billion global crop protection market. Biotalys' lead biofungicide, previously named Biofun-1, was scheduled for US launch in 2022 after EPA certification as a biological pesticide. On March 5, 2020, Biotalys announced the second closing of its Series C financing round, raising an additional €10 million from existing shareholders including Ackermans & van Haaren, Agri Investment Fund, Biovest, Gimv, and Globachem, plus new investor Novalis LifeSciences, bringing the total Series C to €45 million (or €45.1 million per IPO documents). Marijn Dekkers, Chairman of Novalis LifeSciences and former CEO of Bayer AG, joined Biotalys' Board as Observer. Proceeds funded further development, registration, commercial scale production of the lead biofungicide for fruit and vegetable markets, expansion of the discovery platform, and pipeline acceleration for critical crop pests and diseases.
Jul-19Series CAckermans & Van Haaren; Agri Investment Fund; Biovest International; GIMV; K & E; Madeli Participaties; PMV; Qbic Fund; Sofinnova Partners; VIB$39M-Biotalys (formerly AgroSavfe) is a Belgian biotechnology company developing protein-based biocontrols for crop and food protection. The company leverages its proprietary AGROBODY™ bioactive protein platform to create biofungicide and bioinsecticide products that combine the efficacy of chemical pesticides with the safety profile of biological agents. In July 2019, Biotalys closed a Series C financing round that ultimately raised €45 million in total capital across two closings, with the initial closing raising €35 million. All existing investors participated in the round, including GIMV (co-founder and lead investor), Sofinnova Partners, PMV, Agri Investment Fund, K&E, Biovest, Madeli Participaties, VIB, and Qbic Fund, alongside new investor Ackermans & van Haaren, which committed €10 million as part of its first investment in an agrotechnology company. The capital was designated for development and registration of biofungicide and bioinsecticide products, commercial-scale production, and organizational strengthening. The company planned to launch its first biofungicide in the US fruit and vegetables market in 2022, followed by European and global expansions. Biotalys subsequently completed a successful IPO on Euronext Brussels in July 2021, raising €54.6 million in proceeds that were allocated to pipeline development and optimization of the Agrobody Foundry technology platform.
Mar-17Series BAgri Vie; Biovest International; GIMV; Madeli Participaties; PMV; Qbic; Sofinnova Partners; VIB$12M--
Jan-13Series AGIMV; PMV; Qbic; Sofi; VIB$7M-Biotalys was founded in 2013 as a spin-off from the VIB (Flanders Institute for Biotechnology) and is headquartered in Ghent, Belgium. The company develops nanobody-based biocontrol solutions for crop protection, specifically targeting fungicides and insecticides in agriculture. Biotalys employs a proprietary AGROBODY platform designed to deliver novel modes of action at significantly lower R&D and manufacturing costs compared to synthetic alternatives. The company raised funding in 2013 with participation from GIMV, PMV, VIB, and the Agri Investment Fund, supporting early-stage development of its technology platform. Biotalys later went public on Euronext Brussels in July 2021, raising approximately €52.8 million in its IPO.

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Biotalys

When was Biotalys founded?Biotalys was founded in 2013.
Where is Biotalys headquartered?Biotalys is headquartered in Belgium.
How many employees does Biotalys have?As of today, Biotalys has over 64 employees.
Who is the CEO of Biotalys?Biotalys' CEO is Kevin Helash.
Is Biotalys publicly listed?Yes, Biotalys is a public company listed on Euronext Brussels.
What is the stock symbol of Biotalys?Biotalys trades under BTLS ticker.
When did Biotalys go public?Biotalys went public in 2021.
Who are competitors of Biotalys?Biotalys main competitors include Brazil Potash, Arctic Fish Holding, Agrokasa, Terra Santa, Nordic Halibut, FirstFarms, T&G Global, Gobarto, Boa Safra, Seeka.
What is the current market cap of Biotalys?Biotalys' current market cap is $154M.
What is the current revenue of Biotalys?Biotalys' last 12 months revenue is $3M.
What is the current revenue growth of Biotalys?Biotalys revenue growth (NTM/LTM) is 81%.
What is the current EV/Revenue multiple of Biotalys?Current revenue multiple of Biotalys is 45.8x.
Is Biotalys profitable?No, Biotalys is not profitable.
What is the current EBITDA of Biotalys?Biotalys has negative EBITDA and is not profitable.
What is Biotalys' EBITDA margin?Biotalys' last 12 months EBITDA margin is (487%).
What is the current EV/EBITDA multiple of Biotalys?Current EBITDA multiple of Biotalys is (9.4x).
What is the current FCF of Biotalys?Biotalys' last 12 months FCF is ($17M).
What is Biotalys' FCF margin?Biotalys' last 12 months FCF margin is (538%).
What is the current EV/FCF multiple of Biotalys?Current FCF multiple of Biotalys is (8.5x).
How many companies Biotalys has acquired to date?Biotalys hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Biotalys has invested to date?Biotalys hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Biotalys

Lists including Biotalys

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial